search
Back to results

Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia (APRiCE)

Primary Purpose

Acute Respiratory Distress Syndrome (ARDS)

Status
Terminated
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Airway Pressure Release Ventilation (APRV)
Low-tidal volume ventilation
Methylprednisolone
Restrictive fluid therapy
sedo-analgesia titration
Protocolized early enteral nutrition
Protocolized supportive care
Biomarker Assay
Sponsored by
Postgraduate Institute of Medical Education and Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Respiratory Distress Syndrome (ARDS) focused on measuring Pediatric acute respiratory distress syndrome, Mechanical ventilation, Airway pressure release ventilation, Conventional low-tidal volume ventilation

Eligibility Criteria

1 Month - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome:

    1. Acute presentation within 1 week of a known clinical insult or new/ worsening respiratory symptoms
    2. Bilateral opacities on chest imaging - not fully explained by effusions, lobar/lung collapse, or nodules
    3. Respiratory failure is not fully explained by cardiac failure or fluid overload (Echocardiographic assessment to exclude hydrostatic edema)
    4. Impaired oxygenation with PaO2/ FiO2 ratio less than 300 or Oxygenation Index greater than 5.3

Exclusion Criteria:

  • Greater than 24 hours since diagnosis of ARDS
  • Co-existing raised intra-cranial pressure/ any other condition necessitating use of high dose of sedation (likely to suppress spontaneous breathing)
  • Radiologically confirmed air leak prior to randomization - Pneumothorax/ Pulmonary interstitial Emphysema
  • Clinical evidence of significant airway obstruction/ severe bronchospasm / reactive airway disease
  • Have received mechanical ventilation for more than 72 hours (before meeting inclusion criteria)
  • Symptomatic or uncorrected congenital heart disease or a right to left intra-cardiac shunt
  • Any underlying condition that is likely to impair spontaneous respiratory drive/ efforts (Eg: Brainstem dysfunction, neuromuscular paralysis)
  • Underlying chronic diseases (Eg: Cystic fibrosis, Chronic lung disease, etc)

Sites / Locations

  • Pediatric Intensive care unit, Division of Pediatric Critical Care, Advanced Pediatrics Center, Post-graduate Institute of Medical Education & Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Airway pressure release ventilation arm

Low-tidal volume ventilation arm

Arm Description

This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups.

Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups

Outcomes

Primary Outcome Measures

Twenty-eight-day ventilator-free days

Secondary Outcome Measures

Twenty-eight-day survival
Length of PICU stay
The children would be followed up for the duration of their PICU stay
Organ-failure-free-days
Time-to-recovery of lung injury
Number of days for recovery of lung injury (OI<5).
Number of children with adverse events
Children would be observed for incidence of adverse events during the period of PICU stay/ ventilation
All-cause mortality
Spirometry
Forced Expiratory volume during 1st second/ Forced vital capacity
Pediatric Cerebral performance category
Functional outcomes
Pediatric Overall performance category
Spirometry
Forced Expiratory Volume during 1st second / Forced Vital Capacity
Pediatric overall performance category
Assessment of functional outcomes
Pediatric cerebral performance category
Assessment of functional outcomes
Interleukin-6 levels
Arterial lactate levels
Percentage reduction in 'oxygenation Index'
Percentage improvement in oxygenation index at 6 hours of enrolment
Radiological score
Duration of inotropic requirement
Average time frame
Vaso-active inotropic score
Cumulative dose of sedation
Cumulative dose of analgesic
Cumulative dose of neuromuscular blocking agent
Requirement for renal replacement therapy
Need for renal replacement therapy in the first 28 days of PICu stay or discharge/ death whichever is earlier
Pediatric Logistic Organ Dysfunction (PELOD) score

Full Information

First Posted
June 16, 2014
Last Updated
May 17, 2017
Sponsor
Postgraduate Institute of Medical Education and Research
search

1. Study Identification

Unique Protocol Identification Number
NCT02167698
Brief Title
Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia
Acronym
APRiCE
Official Title
A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Terminated
Why Stopped
Increased mortality in the intervention arm at 50% enrolment
Study Start Date
February 2014 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
December 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Postgraduate Institute of Medical Education and Research

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Airway pressure release ventilation (APRV) mode is hypothesized to be superior in terms of lower need for sedation, shorter duration of mechanical ventilation, etc. It is unique and the first worldwide randomized controlled trial on APRV mode in children. We plan to recruit a minimum of 50 children aged (1 month-12 years) in each group. The study is to be conducted at the Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh between March 2014 to March 2016. This trial would recruit children with respiratory failure and early ARDS and, randomize them to receive either conventional ventilation or the APRV mode. Rest of the supportive care has also been protocolized so that both groups receive treatment as per the existing best practices in every aspect. The primary outcome being studied is the number of ventilator-free days. The secondary outcomes include length of PICU stay, hospital stay, organ-failure free days, 28 day & 3 month survival, biomarkers of lung injury (IL-6, IL-8, Angiopoeitin-2, soluble-ICAM-1, etc), functional status, Pulmonary function tests, etc. Funding request would be sent to the Indian Council of Medical Research, New Delhi, India. Assessing lung biomarkers like Interleukin-6 would assess the role of different modes of ventilation in acting as triggers for multi-organ dysfunction as well as for worsening lung injury. This pathbreaking research is likely to open up new avenues upon completion.
Detailed Description
Study setting: 15-bedded pediatric intensive care unit (PICU) of a multi-specialty, tertiary referral and teaching hospital- the Advanced Pediatrics Centre (APC) in Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Study period Recruitment: January 2014 to December 2016 Data Analysis: Jan 2017 to June 2017 Study design An open-labelled, parallel-arm, efficacy/feasibility randomized controlled trial Ethics approval Ethics approval has been obtained from the Institute Ethics Committee. The study has been registered with Clinical Trials Registry - India (CTRI) (ctri.nic.in). Informed consent will be obtained from the parents/legal guardian and the conversation would be recorded using a camera (audio-visual documentation of evidence). Sample size estimation Assuming alpha error of 5% and power of 80% with non-inferiority limit of 4 days (Standard deviation of VFDs being 8.2 days in the conventional low tidal volume ventilation group in pilot trial), sample size was calculated to be 52 per group. As this is a safety and feasibility trial, an interim analysis would be done at 50% enrolment. Enrolment Parents or legal guardians of children who satisfy the above eligibility criteria will be invited by the investigator to participate in the study. Parents are free not to participate, or to withdraw from the study at any point of time. All children, irrespective of their enrollment in the study, will receive standard pediatric intensive care unit (PICU) care as per the unit's existing protocol. An information sheet (in Hindi/ English) furnishing details of the study will be provided to the parents. Given the fact that all these children are sedated and on mechanical ventilation, obtaining assent would not be feasible in this study. Randomization Sequence generation A computer-generated, unstratified, block randomization with variable block sizes will be performed to determine group allocation. A person not involved in the study will perform the random number allocation and prepare opaque, sealed envelopes containing the allocation. Concealment allocation Each pre-sealed opaque envelope would be opened only after obtaining a written consent and audio-visual record of the same. As the randomization is done using a variable block size, and prepared by a statistician not directly involved in the study, there would be no way of predicting the random allocation, thus minimizing the risk of allocation bias. Randomization implementation After parents provide informed consent, randomization would be done within the next one hour and child initiated on appropriate mode of ventilation. The supportive care for both the groups, would be as per the attached supplementary protocols Intervention protocol: The Airway pressure release ventilation (APRV) intervention protocol has been designed based on the available APRV literature as of Dec 2013. Start the child on APRV mode of ventilation with the following settings: P HIGH would determine the degree of baseline lung inflation. A rough estimate can be obtained based on the plateau pressure requirements on the conventional mode of ventilation. Perform an inspiratory hold to ascertain the plateau pressures: If P plateau > 30 cm water, set P HIGH at 30 cm water If P plateau < 30 cm water, set P HIGH at or 1-2 cm above the measured P plateau. Alternatively, if P plateau cannot be measured, P HIGH can be set according to the following guide: PaO2/ FiO2 ratio P High < 250 15-20 < 200 20-25 < 150 25-28 After initiating a particular P HIGH, a clinical assessment of lung volume needs to be followed with a chest radiograph to determine the degree of lung inflation (similar to setting of Mean airway pressure in High frequency oscillatory mode of ventilation). The child's P HIGH is adjusted to maintain optimal lung volume, without clinical or radiological evidence of hyperinflation: no signs of decreased cardiac output/ hypotension and/or the level of the diaphragm visible greater than the ninth rib. Start at T High of 4 seconds; Titrate T High based on oxygenation status. At least 80 -95% of the total cycle time should be spent in T High. Set P Low at Zero cm H2O Set T Low so that expiratory flow decreases by 25 % of peak expiratory flow rate (PEFR); usually 0.1-0.8 seconds. The ratio of T-PEFR to PEFR should be targeted near 75%. This entity needs to be titrated every 2-4 hours and may have to be shortened as lung injury advances. Set Pressure Support at ZERO The number of breaths per minute or number of releases is a function of T High and T Low as depicted below: Weaning from APRV would also be carried out in a structured, protocolized manner. The following strategies would be adopted: As child's clinical condition and oxygenation index improves, and Fraction of inspired oxygen levels are brought down to 0.6, T HIGH is increased in steps of 0.5-2 seconds till it is 10-12 seconds. P HIGH can be subsequently decreased in steps of 2-3 cm H2O till a value of 12-16 is reached. Decrease in P HIGH can be carried out earlier if features of hyperinflation (clinical/radiological) appear at any point. The goal is to reach pressure levels of 12-16 cm H2O and then switch to Continuous positive airway pressure (CPAP) of 6-8 cm H2O, from which child can be extubated directly to nasal prong CPAP or gradually tapered off CPAP to Endotracheal-T piece and subsequently extubated depending on the overall clinical status.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Distress Syndrome (ARDS)
Keywords
Pediatric acute respiratory distress syndrome, Mechanical ventilation, Airway pressure release ventilation, Conventional low-tidal volume ventilation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
52 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Airway pressure release ventilation arm
Arm Type
Experimental
Arm Description
This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups.
Arm Title
Low-tidal volume ventilation arm
Arm Type
Active Comparator
Arm Description
Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
Intervention Type
Device
Intervention Name(s)
Airway Pressure Release Ventilation (APRV)
Other Intervention Name(s)
BiLevel, BiPAP
Intervention Description
This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
Intervention Type
Other
Intervention Name(s)
Low-tidal volume ventilation
Other Intervention Name(s)
Lung-protective ventilation
Intervention Description
This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
Intervention Type
Drug
Intervention Name(s)
Methylprednisolone
Intervention Description
Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
Intervention Type
Other
Intervention Name(s)
Restrictive fluid therapy
Intervention Description
Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols
Intervention Type
Drug
Intervention Name(s)
sedo-analgesia titration
Intervention Type
Other
Intervention Name(s)
Protocolized early enteral nutrition
Intervention Description
Early enteral nutrition and attempt to meet calorie-protein goals
Intervention Type
Other
Intervention Name(s)
Protocolized supportive care
Intervention Description
Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
Intervention Type
Other
Intervention Name(s)
Biomarker Assay
Other Intervention Name(s)
Interleukin 6, Interleukin 8, Angiopoeitin-2, soluble-ICAM-1
Intervention Description
Biomarker Assay for patients in both arms
Primary Outcome Measure Information:
Title
Twenty-eight-day ventilator-free days
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Twenty-eight-day survival
Time Frame
28 days
Title
Length of PICU stay
Description
The children would be followed up for the duration of their PICU stay
Time Frame
Up to 3 months
Title
Organ-failure-free-days
Time Frame
28 days
Title
Time-to-recovery of lung injury
Description
Number of days for recovery of lung injury (OI<5).
Time Frame
Up to 28 days
Title
Number of children with adverse events
Description
Children would be observed for incidence of adverse events during the period of PICU stay/ ventilation
Time Frame
3 years
Title
All-cause mortality
Time Frame
Three months
Title
Spirometry
Description
Forced Expiratory volume during 1st second/ Forced vital capacity
Time Frame
3 months
Title
Pediatric Cerebral performance category
Description
Functional outcomes
Time Frame
6 Months
Title
Pediatric Overall performance category
Time Frame
6 months
Title
Spirometry
Description
Forced Expiratory Volume during 1st second / Forced Vital Capacity
Time Frame
6 months
Title
Pediatric overall performance category
Description
Assessment of functional outcomes
Time Frame
3 months
Title
Pediatric cerebral performance category
Description
Assessment of functional outcomes
Time Frame
3 months
Title
Interleukin-6 levels
Time Frame
72 hours of enrolment
Title
Arterial lactate levels
Time Frame
72 hours
Title
Percentage reduction in 'oxygenation Index'
Description
Percentage improvement in oxygenation index at 6 hours of enrolment
Time Frame
6 hours
Title
Radiological score
Time Frame
48 hours
Title
Duration of inotropic requirement
Description
Average time frame
Time Frame
up to 7 days
Title
Vaso-active inotropic score
Time Frame
72 hours
Title
Cumulative dose of sedation
Time Frame
7 days
Title
Cumulative dose of analgesic
Time Frame
7 days
Title
Cumulative dose of neuromuscular blocking agent
Time Frame
7 days
Title
Requirement for renal replacement therapy
Description
Need for renal replacement therapy in the first 28 days of PICu stay or discharge/ death whichever is earlier
Time Frame
28 days
Title
Pediatric Logistic Organ Dysfunction (PELOD) score
Time Frame
7 days
Other Pre-specified Outcome Measures:
Title
Recruitment rate
Description
Number of children recruited per month on an average
Time Frame
3 years
Title
Rate of enrolment among eligible children
Description
Feasibility outcome Number of children who get enrolled in the study after consent among all eligible children
Time Frame
3 years
Title
Contamination rate
Description
Proportion of recruited children who cross-over from one arm to another
Time Frame
3 years
Title
Attrition rate
Description
Proportion of children who are lost to follow-up at 3 months
Time Frame
3 months
Title
Protocol adherence rate
Description
Proportion of children where all supportive care protocols are adhered to.
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome: Acute presentation within 1 week of a known clinical insult or new/ worsening respiratory symptoms Bilateral opacities on chest imaging - not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure is not fully explained by cardiac failure or fluid overload (Echocardiographic assessment to exclude hydrostatic edema) Impaired oxygenation with PaO2/ FiO2 ratio less than 300 or Oxygenation Index greater than 5.3 Exclusion Criteria: Greater than 24 hours since diagnosis of ARDS Co-existing raised intra-cranial pressure/ any other condition necessitating use of high dose of sedation (likely to suppress spontaneous breathing) Radiologically confirmed air leak prior to randomization - Pneumothorax/ Pulmonary interstitial Emphysema Clinical evidence of significant airway obstruction/ severe bronchospasm / reactive airway disease Have received mechanical ventilation for more than 72 hours (before meeting inclusion criteria) Symptomatic or uncorrected congenital heart disease or a right to left intra-cardiac shunt Any underlying condition that is likely to impair spontaneous respiratory drive/ efforts (Eg: Brainstem dysfunction, neuromuscular paralysis) Underlying chronic diseases (Eg: Cystic fibrosis, Chronic lung disease, etc)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Saptharishi L G, MBBS, MD
Organizational Affiliation
DM (Pediatric Critical Care) Senior Resident, Division of Pediatric critical care, Dept Of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, INDIA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jayashree Muralidharan, MBBS, MD
Organizational Affiliation
Additional Professor, Division of Pediatric critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sunit C Singhi, MBBS, MD
Organizational Affiliation
Chief, Division of Pediatric Critical Care, Professor & Head, Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Arun Bansal, MBBS, MD
Organizational Affiliation
Assistant Professor, Division of Pediatric Critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India
Official's Role
Study Chair
Facility Information:
Facility Name
Pediatric Intensive care unit, Division of Pediatric Critical Care, Advanced Pediatrics Center, Post-graduate Institute of Medical Education & Research
City
Chandigarh
ZIP/Postal Code
160012
Country
India

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Permission would have to be sought from institution in this regard.
Citations:
PubMed Identifier
24156844
Citation
Andrews P, Habashi N. Airway pressure release ventilation. Curr Probl Surg. 2013 Oct;50(10):462-70. doi: 10.1067/j.cpsurg.2013.08.010. No abstract available.
Results Reference
background
PubMed Identifier
24064877
Citation
Andrews PL, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O'Toole RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of airway pressure release ventilation may reduce mortality in high-risk trauma patients: a systematic review of observational trauma ARDS literature. J Trauma Acute Care Surg. 2013 Oct;75(4):635-41. doi: 10.1097/TA.0b013e31829d3504.
Results Reference
background
PubMed Identifier
24026214
Citation
Emr B, Gatto LA, Roy S, Satalin J, Ghosh A, Snyder K, Andrews P, Habashi N, Marx W, Ge L, Wang G, Dean DA, Vodovotz Y, Nieman G. Airway pressure release ventilation prevents ventilator-induced lung injury in normal lungs. JAMA Surg. 2013 Nov;148(11):1005-12. doi: 10.1001/jamasurg.2013.3746. Erratum In: JAMA Surg. 2016 Dec 1;151(12 ):1193.
Results Reference
background
PubMed Identifier
23799354
Citation
Roy SK, Emr B, Sadowitz B, Gatto LA, Ghosh A, Satalin JM, Snyder KP, Ge L, Wang G, Marx W, Dean D, Andrews P, Singh A, Scalea T, Habashi N, Nieman GF. Preemptive application of airway pressure release ventilation prevents development of acute respiratory distress syndrome in a rat traumatic hemorrhagic shock model. Shock. 2013 Sep;40(3):210-6. doi: 10.1097/SHK.0b013e31829efb06.
Results Reference
background
PubMed Identifier
23247119
Citation
Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P, Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y, Nieman G. Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. Shock. 2013 Jan;39(1):28-38. doi: 10.1097/SHK.0b013e31827b47bb.
Results Reference
background
PubMed Identifier
29641221
Citation
Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1199-1207. doi: 10.1164/rccm.201705-0989OC.
Results Reference
derived

Learn more about this trial

Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia

We'll reach out to this number within 24 hrs